Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis

Young Hak Kim, Bong Ki Lee, Duk Woo Park, Kyoung Ha Park, Bong Ryong Choi, Cheol Whan Lee, Myeong Ki Hong, Jae Joong Kim, Seong Wook Park, Seung Jung Park

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

This study compared the safety and efficacy of repeat percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SESs) with conventional therapies for restenosis after drug-eluting stent placement. Fifty-five consecutive patients with 58 restenotic lesions (31 treated with SESs and 27 treated with paclitaxel-eluting stents) underwent PCI using SESs (33 lesions) or conventional therapies comprising cutting balloon angioplasty alone (11 lesions) or intracoronary brachytherapy (14 lesions). Baseline characteristics were similar for the 2 groups, except for greater edge involvement (75.8% vs 36.0%, p = 0.002) and less stent expansion (0.74 ± 0.17 vs 0.95 ± 0.21, p = 0.006) in the SES group than in the conventional group. The SES group achieved a greater postprocedural luminal gain than the conventional group (1.98 ± 0.50 vs 1.22 ± 0.48 mm, p <0.001). Follow-up angiography showed that late luminal loss (0.27 ± 0.56 vs 0.76 ± 0.84 mm, p = 0.021) and recurrent angiographic restenosis rate (3.6% vs 35.0%, p = 0.006) were lower in the SES group than in the conventional group. The repeated target lesion revascularization-free survival rates at 1 year were 96.7 ± 3.2% for the SES group and 91.7 ± 5.6% for the conventional group (p = 0.399). In conclusion, use of SESs was associated with a lower recurrent restenosis rate compared with conventional therapies.

Original languageEnglish
Pages (from-to)1451-1454
Number of pages4
JournalAmerican Journal of Cardiology
Volume98
Issue number11
DOIs
Publication statusPublished - 2006 Dec 1

Fingerprint

Coronary Restenosis
Drug-Eluting Stents
Sirolimus
Stents
Therapeutics
Percutaneous Coronary Intervention
Balloon Angioplasty
Brachytherapy
Paclitaxel
Angiography
Survival Rate

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Young Hak ; Lee, Bong Ki ; Park, Duk Woo ; Park, Kyoung Ha ; Choi, Bong Ryong ; Lee, Cheol Whan ; Hong, Myeong Ki ; Kim, Jae Joong ; Park, Seong Wook ; Park, Seung Jung. / Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis. In: American Journal of Cardiology. 2006 ; Vol. 98, No. 11. pp. 1451-1454.
@article{4f8dad4ff77e48aebfbaeba060bfe52e,
title = "Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis",
abstract = "This study compared the safety and efficacy of repeat percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SESs) with conventional therapies for restenosis after drug-eluting stent placement. Fifty-five consecutive patients with 58 restenotic lesions (31 treated with SESs and 27 treated with paclitaxel-eluting stents) underwent PCI using SESs (33 lesions) or conventional therapies comprising cutting balloon angioplasty alone (11 lesions) or intracoronary brachytherapy (14 lesions). Baseline characteristics were similar for the 2 groups, except for greater edge involvement (75.8{\%} vs 36.0{\%}, p = 0.002) and less stent expansion (0.74 ± 0.17 vs 0.95 ± 0.21, p = 0.006) in the SES group than in the conventional group. The SES group achieved a greater postprocedural luminal gain than the conventional group (1.98 ± 0.50 vs 1.22 ± 0.48 mm, p <0.001). Follow-up angiography showed that late luminal loss (0.27 ± 0.56 vs 0.76 ± 0.84 mm, p = 0.021) and recurrent angiographic restenosis rate (3.6{\%} vs 35.0{\%}, p = 0.006) were lower in the SES group than in the conventional group. The repeated target lesion revascularization-free survival rates at 1 year were 96.7 ± 3.2{\%} for the SES group and 91.7 ± 5.6{\%} for the conventional group (p = 0.399). In conclusion, use of SESs was associated with a lower recurrent restenosis rate compared with conventional therapies.",
author = "Kim, {Young Hak} and Lee, {Bong Ki} and Park, {Duk Woo} and Park, {Kyoung Ha} and Choi, {Bong Ryong} and Lee, {Cheol Whan} and Hong, {Myeong Ki} and Kim, {Jae Joong} and Park, {Seong Wook} and Park, {Seung Jung}",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.amjcard.2006.07.027",
language = "English",
volume = "98",
pages = "1451--1454",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "11",

}

Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis. / Kim, Young Hak; Lee, Bong Ki; Park, Duk Woo; Park, Kyoung Ha; Choi, Bong Ryong; Lee, Cheol Whan; Hong, Myeong Ki; Kim, Jae Joong; Park, Seong Wook; Park, Seung Jung.

In: American Journal of Cardiology, Vol. 98, No. 11, 01.12.2006, p. 1451-1454.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison With Conventional Therapies of Repeated Sirolimus-Eluting Stent Implantation for the Treatment of Drug-Eluting Coronary Stent Restenosis

AU - Kim, Young Hak

AU - Lee, Bong Ki

AU - Park, Duk Woo

AU - Park, Kyoung Ha

AU - Choi, Bong Ryong

AU - Lee, Cheol Whan

AU - Hong, Myeong Ki

AU - Kim, Jae Joong

AU - Park, Seong Wook

AU - Park, Seung Jung

PY - 2006/12/1

Y1 - 2006/12/1

N2 - This study compared the safety and efficacy of repeat percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SESs) with conventional therapies for restenosis after drug-eluting stent placement. Fifty-five consecutive patients with 58 restenotic lesions (31 treated with SESs and 27 treated with paclitaxel-eluting stents) underwent PCI using SESs (33 lesions) or conventional therapies comprising cutting balloon angioplasty alone (11 lesions) or intracoronary brachytherapy (14 lesions). Baseline characteristics were similar for the 2 groups, except for greater edge involvement (75.8% vs 36.0%, p = 0.002) and less stent expansion (0.74 ± 0.17 vs 0.95 ± 0.21, p = 0.006) in the SES group than in the conventional group. The SES group achieved a greater postprocedural luminal gain than the conventional group (1.98 ± 0.50 vs 1.22 ± 0.48 mm, p <0.001). Follow-up angiography showed that late luminal loss (0.27 ± 0.56 vs 0.76 ± 0.84 mm, p = 0.021) and recurrent angiographic restenosis rate (3.6% vs 35.0%, p = 0.006) were lower in the SES group than in the conventional group. The repeated target lesion revascularization-free survival rates at 1 year were 96.7 ± 3.2% for the SES group and 91.7 ± 5.6% for the conventional group (p = 0.399). In conclusion, use of SESs was associated with a lower recurrent restenosis rate compared with conventional therapies.

AB - This study compared the safety and efficacy of repeat percutaneous coronary intervention (PCI) using sirolimus-eluting stents (SESs) with conventional therapies for restenosis after drug-eluting stent placement. Fifty-five consecutive patients with 58 restenotic lesions (31 treated with SESs and 27 treated with paclitaxel-eluting stents) underwent PCI using SESs (33 lesions) or conventional therapies comprising cutting balloon angioplasty alone (11 lesions) or intracoronary brachytherapy (14 lesions). Baseline characteristics were similar for the 2 groups, except for greater edge involvement (75.8% vs 36.0%, p = 0.002) and less stent expansion (0.74 ± 0.17 vs 0.95 ± 0.21, p = 0.006) in the SES group than in the conventional group. The SES group achieved a greater postprocedural luminal gain than the conventional group (1.98 ± 0.50 vs 1.22 ± 0.48 mm, p <0.001). Follow-up angiography showed that late luminal loss (0.27 ± 0.56 vs 0.76 ± 0.84 mm, p = 0.021) and recurrent angiographic restenosis rate (3.6% vs 35.0%, p = 0.006) were lower in the SES group than in the conventional group. The repeated target lesion revascularization-free survival rates at 1 year were 96.7 ± 3.2% for the SES group and 91.7 ± 5.6% for the conventional group (p = 0.399). In conclusion, use of SESs was associated with a lower recurrent restenosis rate compared with conventional therapies.

UR - http://www.scopus.com/inward/record.url?scp=33751193459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751193459&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2006.07.027

DO - 10.1016/j.amjcard.2006.07.027

M3 - Article

C2 - 17126648

AN - SCOPUS:33751193459

VL - 98

SP - 1451

EP - 1454

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 11

ER -